Advocacy Wealth Management LLC Invests $802,000 in DexCom, Inc. $DXCM

Advocacy Wealth Management LLC acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 12,077 shares of the medical device company’s stock, valued at approximately $802,000.

A number of other large investors also recently made changes to their positions in DXCM. Norges Bank acquired a new stake in shares of DexCom in the 4th quarter valued at approximately $483,356,000. Holocene Advisors LP bought a new stake in shares of DexCom in the third quarter valued at about $163,964,000. CIBC Private Wealth Group LLC boosted its position in DexCom by 374.3% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock worth $195,666,000 after acquiring an additional 2,294,709 shares during the last quarter. Vanguard Group Inc. boosted its holdings in DexCom by 2.3% during the third quarter. Vanguard Group Inc. now owns 49,456,043 shares of the medical device company’s stock worth $3,327,897,000 after purchasing an additional 1,133,638 shares during the last quarter. Finally, Intermede Investment Partners Ltd bought a new position in shares of DexCom in the 4th quarter valued at about $60,351,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Buying and Selling at DexCom

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the sale, the director directly owned 25,007 shares of the company’s stock, valued at $1,500,670.07. The trade was a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the completion of the transaction, the insider owned 382,482 shares in the company, valued at $27,538,704. This represents a 6.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 42,694 shares of company stock valued at $3,029,267. Insiders own 0.28% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Mizuho set a $75.00 target price on shares of DexCom in a report on Friday, May 1st. Sanford C. Bernstein set a $77.00 price objective on shares of DexCom in a research note on Friday, May 1st. Bank of America reduced their price objective on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Barclays reiterated an “underweight” rating and set a $64.00 price target (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Finally, William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $83.04.

DexCom Trading Up 5.2%

Shares of DXCM opened at $76.62 on Tuesday. The business’s 50-day moving average price is $65.04 and its 200-day moving average price is $67.15. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The stock has a market cap of $29.57 billion, a PE ratio of 32.74, a P/E/G ratio of 1.14 and a beta of 1.45. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter last year, the company posted $0.32 EPS. The company’s revenue for the quarter was up 15.0% on a year-over-year basis. On average, equities analysts forecast that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.